Analysts Set Phreesia, Inc. (NYSE:PHR) Target Price at $29.12

Phreesia, Inc. (NYSE:PHR) has been given a consensus recommendation of “Moderate Buy” by the nineteen research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $29.1176.

A number of equities analysts have recently weighed in on PHR shares. JPMorgan Chase & Co. lowered their target price on Phreesia from $29.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 20th. Zacks Research lowered shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Wall Street Zen downgraded shares of Phreesia from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 8th. Royal Bank Of Canada began coverage on shares of Phreesia in a research note on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price objective on the stock. Finally, Robert W. Baird reduced their price objective on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, December 10th.

Phreesia Stock Up 5.4%

Shares of NYSE:PHR opened at $11.81 on Tuesday. The business’s 50 day simple moving average is $13.23 and its two-hundred day simple moving average is $18.67. The firm has a market cap of $711.72 million, a P/E ratio of -118.04 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia has a 52-week low of $10.75 and a 52-week high of $32.76.

Insiders Place Their Bets

In other Phreesia news, CFO Balaji Gandhi sold 8,009 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09. Following the completion of the sale, the chief financial officer directly owned 156,231 shares of the company’s stock, valued at approximately $2,657,489.31. The trade was a 4.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Amy Beth Vanduyn sold 2,602 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $44,260.02. Following the completion of the sale, the senior vice president directly owned 160,238 shares of the company’s stock, valued at approximately $2,725,648.38. This trade represents a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 60,353 shares of company stock worth $1,006,528 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. grew its holdings in Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock worth $400,000 after buying an additional 375 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Phreesia by 2.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company’s stock valued at $569,000 after acquiring an additional 540 shares in the last quarter. Diversified Trust Co boosted its holdings in Phreesia by 1.7% during the 3rd quarter. Diversified Trust Co now owns 45,822 shares of the company’s stock worth $1,078,000 after acquiring an additional 780 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Phreesia by 1.3% during the 3rd quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock worth $1,475,000 after acquiring an additional 812 shares during the last quarter. Finally, Bank of Montreal Can grew its stake in shares of Phreesia by 9.2% in the 2nd quarter. Bank of Montreal Can now owns 11,277 shares of the company’s stock worth $321,000 after acquiring an additional 950 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.